Peptide record

TPDB92060

Magainin B Magainin2wisc Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity modified_plain modified
23 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92060
Magainin B Magainin2wisc
Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab AFP-GFuse Antifungipept CAFPdb i2APP HemoPI Hemolytic2 PD_Hemolysis
modified_plain
Yes
A 23-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
GIGKFLHAAKKFAKAFVAEIMNS-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
23 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antibacterial Anticancer Activity
Xenopus laevis FLAK peptides Activity
Evidence Records 16 records
Evidence 1 Activity

Activity

IC50
IC50=17 µg/ml
Anticancer
17 µg/mL

Target

Lymphoma Cancer
U-937
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=12 µg/ml
Anticancer
12 µg/mL

Target

Leukemia Cancer
8402
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 3 Activity

Activity

IC50
IC50=27 µg/ml
Anticancer
27 µg/mL

Target

Hematopoietic Cancer
SSKT-1
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 4 Activity

Activity

IC50
IC50=28 µg/ml
Anticancer
28 µg/mL

Target

Ovarian Cancer
Daudi
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 5 Activity

Activity

IC50
IC50=30 µg/ml
Anticancer
30 µg/mL

Target

Leukemia Cancer
MLA
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 6 Activity

Activity

IC50
IC50=23 µg/ml
Anticancer
23 µg/mL

Target

Lymphoma Cancer
Raji
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 7 Activity

Activity

IC50
IC50=32 µg/ml
Anticancer
32 µg/mL

Target

Leukemia Cancer
K-562
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 8 Activity

Activity

IC50
IC50=32 µg/ml
Anticancer
32 µg/mL

Target

Ewing sarcoma
CHP-100
Blood

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 9 Activity

Activity

IC50
IC50=37 µg/ml
Anticancer
37 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 10 Activity

Activity

IC50
IC50=41 µg/ml
Anticancer
41 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1990
Evidence 11 Activity

Activity

LD50
LD50 =22 µg/ml
Anticancer
22 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 12 Activity

Activity

LD50
LD50 =60 µg/ml
Anticancer
60 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 13 Activity

Activity

LD50
LD50 =130 µg/ml
Anticancer
130 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 14 Activity

Activity

LD50
LD50 =60 µg/ml
Anticancer
60 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 15 Activity

Activity

LD50
LD50 =45 µg/ml
Anticancer
45 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 16 Activity

Activity

LD50
LD50 =125 µg/ml
Anticancer
125 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2